Implantable Neurostimulators Market Report 2025

This implantable neurostimulators market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The implantable neurostimulators market size has grown rapidly in recent years. It will grow from $6.06 billion in 2024 to $6.76 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to rising prevalence of chronic pain, increasing aging population, improved reimbursement policies, government funding and support, and expanding indications.

The implantable neurostimulators market size is expected to see rapid growth in the next few years. It will grow to $10.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing prevalence of neurological disorders, growth in minimally invasive procedures, healthcare expenditure growth, rising demand for non-opioid pain management, collaborations and partnerships. Major trends in the forecast period include technology advancements, diversification beyond chronic pain, miniaturization and AI-powered personalization, remote monitoring and digital therapeutics, product innovation.

The growing prevalence of neurological disorders is expected to drive the expansion of the implantable neurostimulators market. Neurological disorders affect the nervous system, including the brain and spinal cord, impacting functions such as movement and cognition. The rise in such disorders is largely attributed to the aging population, as longer lifespans increase susceptibility to conditions such as Alzheimer's and Parkinson's disease. Implantable neurostimulators are devices that deliver electrical impulses to manage symptoms, such as tremors and pain, associated with conditions such as epilepsy and Parkinson's. For instance, the World Federation of Neurology reported in October 2023 that over 40% of the global population currently suffers from some form of neurological condition, with this burden expected to nearly double by 2050. This increasing prevalence is fueling growth in the implantable neurostimulators market.

Key players in the implantable neurostimulators market are focusing on developing advanced technologies, such as rechargeable spinal cord stimulators, to improve patient comfort, simplify surgical procedures, and enhance pain management treatments. Rechargeable spinal cord stimulators are devices implanted to relieve chronic pain by delivering electrical signals to the spinal cord. For example, in December 2022, Abbott Laboratories, a U.S.-based healthcare product manufacturer, received FDA approval for the Eterna spinal cord stimulation (SCS) system. This device, the smallest of its kind, is designed for chronic pain relief and utilizes Abbott's proprietary BurstDR stimulation technology, which mimics natural brain patterns to achieve 23% more effective pain reduction than traditional methods. The Eterna SCS system also features Xtend energy technology, requiring as few as five charges per year, reducing the need for frequent recharging. It supports full-body MRI scans and is upgradeable for future advancements.

In September 2023, Amber Therapeutics Ltd., a medical technology company based in the UK, acquired Bioinduction Ltd. for an undisclosed sum. This acquisition will allow Bioinduction to strengthen its ability to develop innovative neuromodulation therapies, particularly aimed at treating mixed urinary incontinence (MUI). Bioinduction Ltd. specializes in creating unique implantable neuromodulation devices within the medical technology sector.

Major companies operating in the implantable neurostimulators market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, LivaNova plc, Inspire Medical Systems Inc., Nevro Corporation, Axonics Inc., Cirtec Medical Systems LLC, SPR Therapeutics Inc., BlueWind Medical Ltd., NeuroPace Inc., Bioness Inc., ReShape Lifesciences Inc., Synapse Biomedical Inc., Autonomic Technologies Inc., Comphya SA, Mainstay Medical Holdings plc, Sigenics Inc., Nalu Medical Inc., Aleva Neurotherapeutics SA, Nuvectra Corporation.

North America was the largest region in the implantable neurostimulators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable neurostimulators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable neurostimulators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Implantable neurostimulators are medical devices designed to deliver electrical impulses to targeted areas of the nervous system to modify or regulate nerve activity. These devices are commonly used to treat chronic pain, neurological disorders, and other conditions involving impaired nerve function. The primary goal of an implantable neurostimulator is to either regulate abnormal nerve signals or stimulate underactive nerves.

The key types of implantable neurostimulators include spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and others. Spinal cord stimulators (SCS) are designed to send electrical impulses to the spinal cord, blocking pain signals before they reach the brain. These devices are used for a variety of conditions, including pain management, Parkinson's disease, urinary and fecal incontinence, epilepsy, gastroparesis, and more. End users of these devices include hospitals, ambulatory surgical centers (ASCs), and others.

The implantable neurostimulators market research report is one of a series of new reports that provides implantable neurostimulators market statistics, including implantable neurostimulators industry global market size, regional shares, competitors with a implantable neurostimulators market share, detailed implantable neurostimulators market segments, market trends and opportunities, and any further data you may need to thrive in the implantable neurostimulators industry. This implantable neurostimulators market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The implantable neurostimulators market consists of sales of peripheral nerve stimulators, myostimulators, spinal cord stimulators, and brain stimulators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.